FULCRUM THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.255 USD | +4.36% |
|
+10.14% | +23.85% |
Presenter SpeechLalita Sundarrajan (Analysts)Hi, everyone. Good afternoon, and welcome to the ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Companyâs clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
7.91
USD
Average target price
14.25
USD
Spread / Average Target
+80.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.85% | 492M | |
| +28.99% | 49.18B | |
| +0.82% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.30% | 26.09B | |
| -22.63% | 18.71B | |
| +8.06% | 13.26B | |
| +32.17% | 12.32B | |
| -0.52% | 11.99B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Transcript : Fulcrum Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 04
